PDCD1 and hepatocellular carcinoma: Therefore, personalized immunotherapy for HCC can be developed by reference to the mechanisms responsible for the immunosuppressive activities of TAMs and related factors, such as blockage of PD-1, PD-L1/L2, Fas L and TRAIL, and FcγRI expression in TAMs, in order to enhance the efficacy of anti-PD-1/PD-L1 immunotherapy and improve the survival rate.